Tags

Type your tag names separated by a space and hit enter

[Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy].
Yakugaku Zasshi. 2019; 139(1):63-67.YZ

Abstract

Epstein-Barr virus (EBV), a human oncogenic virus, is a B cell-tropic herpesvirus and has the ability to immortalize normal B cells during latent infection. The Epstein-Barr nuclear antigen 1 (EBNA1) protein of EBV is expressed in the most EBV latently infected cells and binds to a specific viral genome region termed "oriP" (origin of plasmid replication) to maintain the stability of the approximately 170 kb double-stranded circular virus genomic DNA (episome) in cells. EBV elimination is thought to inhibit progression of EBV-associated malignancies, and the EBNA1-dependent mechanisms for EBV episome replication and maintenance are considered to be novel molecular targets for anti-EBV therapy. We have explored small-molecule compounds that can inhibit the binding between EBNA1 protein and oriP and found one pyrrole imidazole polyamide named DSE3 which can also inhibit EBV-mediated immortalization of normal B cells. These data suggested that an EBNA1-targeting strategy could be useful to combat EBV-associated malignancies.

Authors+Show Affiliations

Division of Chemotherapy, Faculty of Pharmacy, Keio University.

Pub Type(s)

Journal Article
Review

Language

jpn

PubMed ID

30606931

Citation

Noguchi, Kohji. "[Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy]." Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan, vol. 139, no. 1, 2019, pp. 63-67.
Noguchi K. [Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy]. Yakugaku Zasshi. 2019;139(1):63-67.
Noguchi, K. (2019). [Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy]. Yakugaku Zasshi : Journal of the Pharmaceutical Society of Japan, 139(1), 63-67. https://doi.org/10.1248/yakushi.18-00164-1
Noguchi K. [Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy]. Yakugaku Zasshi. 2019;139(1):63-67. PubMed PMID: 30606931.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Epstein-Barr Virus Genome Replication as a Molecular Target for Cancer Therapy]. A1 - Noguchi,Kohji, PY - 2019/1/5/entrez PY - 2019/1/5/pubmed PY - 2019/4/23/medline KW - DNA replication KW - Epstein-Barr virus KW - molecular target SP - 63 EP - 67 JF - Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan JO - Yakugaku Zasshi VL - 139 IS - 1 N2 - Epstein-Barr virus (EBV), a human oncogenic virus, is a B cell-tropic herpesvirus and has the ability to immortalize normal B cells during latent infection. The Epstein-Barr nuclear antigen 1 (EBNA1) protein of EBV is expressed in the most EBV latently infected cells and binds to a specific viral genome region termed "oriP" (origin of plasmid replication) to maintain the stability of the approximately 170 kb double-stranded circular virus genomic DNA (episome) in cells. EBV elimination is thought to inhibit progression of EBV-associated malignancies, and the EBNA1-dependent mechanisms for EBV episome replication and maintenance are considered to be novel molecular targets for anti-EBV therapy. We have explored small-molecule compounds that can inhibit the binding between EBNA1 protein and oriP and found one pyrrole imidazole polyamide named DSE3 which can also inhibit EBV-mediated immortalization of normal B cells. These data suggested that an EBNA1-targeting strategy could be useful to combat EBV-associated malignancies. SN - 1347-5231 UR - https://www.unboundmedicine.com/medline/citation/30606931/[Epstein_Barr_Virus_Genome_Replication_as_a_Molecular_Target_for_Cancer_Therapy]_ L2 - https://dx.doi.org/10.1248/yakushi.18-00164-1 DB - PRIME DP - Unbound Medicine ER -